This post was originally published on this site Living with a chronic disease like Lambert-Eaton myasthenic syndrome (LEMS) can be very stressful. You may feel like you’ve lost control over your life after being diagnosed. Here are some tips to help reduce stress, and improve your mental and physical health. Get enough sleep It’s easy…
This post was originally published on this site Surface Oncology is requesting approval to open a Phase 1/1b clinical trial testing SRF617, an anti-CD39 antibody, either alone or in combination with other cancer immunotherapies in people with advanced solid tumors. The request was submitted to the U.S. Food and Drug Administration (FDA), and the company also intends to…
This post was originally published on this site Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow memory and…
This post was originally published on this site Five years ago, Will Schuller was thoroughly enjoying his senior year in high school when he began experiencing symptoms of Lambert-Eaton myasthenic syndrome (LEMS). He was in the marching band, running 25 miles a week, and taking four Advanced Placement classes and one honors class when his…
This post was originally published on this site Learning you have a rare disorder like Lambert-Eaton myasthenic syndrome (LEMS) can be frightening. Among the first questions many people have is: How will my lifespan be affected? The answer often isn’t clear-cut. What is life expectancy? Life expectancy is an estimate of how long people will live. That…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The agency’s decision was based on promising interim results from two ongoing Phase 3 clinical trials, the ELEVATE-TN (NCT02475681) and ASCEND (NCT02970318)…
This post was originally published on this site Spontaneity is what I miss most about my pre-LEMS life. No longer can I hop in the car and go to a concert, the beach, or a quick weekend away without planning around meds and treatment schedules. Even with the best-laid plans, I find myself pulling over…
This post was originally published on this site A newly opened Phase 2 clinical trial will test the sensitivity of new imaging tool for plaque buildup in the brains of people with mild cognitive impairment and dementia due to Alzheimer’s disease, Aprinoia Therapeutics announced. The trial is set to enroll 130 adults, 50 to 85 years…
This post was originally published on this site Carmustine for Injection, a generic version of the chemotherapy BiCNU, has been launched in the U.S to treat people with multiple myeloma and other types of cancer. This follows the decision by the U.S. Food and Drug Administration (FDA) to approve STI Pharma‘s abbreviated new drug application — specific…
This post was originally published on this site Acthar Gel (repository corticotropin injection, or RCI) can improve sarcoidosis symptoms, a real-world study shows. Titled “Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records,” the study was published in the journal Therapeutic Advances in Respiratory Disease. Acthar Gel, marketed by Mallinckrodt Pharmaceuticals,…
